DUBLIN , Feb. 8, 2024 /PRNewswire/ -- The 'Chagas Disease: American trypanosomiasis Market' report has been added to ResearchAndMarkets.com's offering.

都柏林，2024年2月8日/PRNewswire/--ResearchAndMarkets.com的产品中增加了“恰加斯病：美国锥虫病市场”报告。

The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status. It is believed that Chagas sickness is a neglected tropical illness. It is widespread throughout 21 American countries, but it can spread to non-endemic nations worldwide through the movement of infected individuals.The effects of CD extend beyond Latin American rural communities where vector-borne transmission - diseases spread by insects - occurs.

原生动物克氏锥虫是恰加斯病（CD）的病因，也称为美国锥虫病，这是一种慢性，全身性，寄生虫病，具有与低社会经济地位相关的重大风险因素。据信查加斯病是一种被忽视的热带疾病。它在21个美国国家广泛传播，但它可以通过感染者的流动传播到世界各地的非流行国家。镉的影响超出了拉丁美洲农村社区，那里发生了媒介传播的疾病，即昆虫传播的疾病。

The epidemiology and geographic distribution of CD have changed due to significant population shifts from rural to urban areas in Latin America and other parts of the world. Control measures should concentrate on preventing transmission from organ transplants, blood transfusions and mother-to-child (congenital) transmission in the U.S.

由于拉丁美洲和世界其他地区人口从农村地区向城市地区的大量转移，CD的流行病学和地理分布发生了变化。在美国，控制措施应集中于防止器官移植、输血和母婴（先天性）传播。

and other areas where CD is currently present but is not endemic.Treatment for T. cruzi infection can begin as soon as the infection occurs. Antiparasitic therapy may stop or slow the progression of chronic illnesses in infected people, as well as stop infections from spreading from mother to child..

以及目前存在CD但不是地方病的其他地区。克氏锥虫感染的治疗可以在感染发生后立即开始。抗寄生虫治疗可以阻止或减缓感染者慢性疾病的进展，并阻止感染从母亲传播到孩子。。

Two therapeutic modalities have the potential to save lives:

两种治疗方式有可能挽救生命：

Antiparasitic medication, which eliminates the parasite.

消除寄生虫的抗寄生虫药物。

Symptomatic therapy, which is intended to control infection-related symptoms and indicators.

对症治疗，旨在控制感染相关症状和指标。

Treatment with antiparasitic drugs is most beneficial early in the course of infection, albeit not exclusively for acute or critical cases. There are two kinds of treatments offered in the U.S. Benznidazole is available commercially and has been licensed by the FDA for use in children ages 2 to 12. Pharmacies can buy LAMPIT (nifurtimox) commercially from several medication wholesalers.

抗寄生虫药物治疗在感染早期最为有益，尽管不限于急性或危重病例。美国提供两种治疗方法。苯硝唑可在市场上买到，并已获得FDA许可用于2至12岁的儿童。药店可以从几家药品批发商那里购买LAMPIT（硝呋替莫）。

It is FDA-approved for treating children under the age of 18. Healthcare providers can consult with Centers for Disease Control and Prevention (CDC) personnel regarding patient care, and for the most part, therapy does not require hospitalization..

它被FDA批准用于治疗18岁以下的儿童。医疗保健提供者可以咨询疾病控制和预防中心（CDC）人员有关患者护理的信息，并且在大多数情况下，治疗不需要住院治疗。。

The research report provides a thorough overview of the Chagas Disease market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.The Report Includes.

该研究报告全面概述了恰加斯病市场。本报告通过流行病学和区域市场分析了CD市场趋势，重点介绍了当前市场，并提供了详细的竞争环境分析。本报告的范围涵盖整个拉丁美洲的治疗。该报告包括。

An overview of the global chagas disease (T. cruzi infection) market

全球恰加斯病（克氏锥虫感染）市场概述

Analyses of the global market trends, with historical market revenue from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028

分析全球市场趋势，包括2021年至2022年的历史市场收入、2023年的估计、2024年的预测以及到2028年的复合年增长率（CAGR）预测

Estimate of the market size and revenue forecast for global chagas disease market, and corresponding market share analysis based on the product type, treatment, and region

估计全球恰加斯病市场的市场规模和收入预测，并根据产品类型、治疗方法和地区进行相应的市场份额分析

Overview of the significant driving trends and challenges that affect the global market and its vendor landscape

概述影响全球市场及其供应商格局的重要驱动趋势和挑战

Review of the epidemiology of chagas disease and potential of key marketed drugs and recent approvals

恰加斯病的流行病学回顾以及关键上市药物的潜力和最近的批准

Discussion of sustainability trends and factors in the chagas disease market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed

讨论南美锥虫病市场的可持续发展趋势和因素，重点是消费者态度、ESG评分分析、ESG的未来、案例研究以及遵循的ESG实践

Analysis of the competitive intelligence based on recent developments, key financials and segmental revenues, and product launch strategies

基于最新发展、关键财务和分部收入以及产品发布策略的竞争情报分析

Detailed profiles of leading market participants Bayer and Insud Pharma, providing a descriptive overview of their respective businesses

拜耳和因苏德制药主要市场参与者的详细概况，提供了各自业务的描述性概述

Key Topics Covered: Chapter 1 Introduction

涵盖的主要主题：第1章简介

Chapter 2 Summary and HighlightsChapter 3 Market Overview

第2章概述和亮点第3章市场概述

History

历史

Trypanosoma Cruzi

克氏锥虫

Vector and T. cruzi

Vector和T.cruzi

Transmission Routes

传输线路

Clinical Forms

临床形式

Future Perspectives

未来展望

Novel Drugs

新药

Chapter 4 Chagas Disease by Drugs

第四章药物引起的恰加斯病

Benznidazole

苯硝唑

Toxicity of Benznidazole

苯硝唑的毒性

Nifurtimox

硝呋替莫

Toxicity of Nifurtimox

硝呋替莫的毒性

Chapter 5 Chagas Disease by Diagnosis

第五章查加斯病的诊断

Serology (Antibody Detection)

血清学（抗体检测）

Molecular Testing

分子检测

Chapter 6 Competitive Landscape

第6章竞争格局

Chapter 7 Company Profiles

第7章公司简介

Bayer

拜耳

Insud Pharma

Insud Pharma

For more information about this report visit https://www.researchandmarkets.com/r/oiznbg

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/oiznbg

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。

Media Contact:

媒体联系人：

Research and MarketsLaura Wood, Senior Manager[email protected]

研究与市场高级经理Slaura Wood[受电子邮件保护]

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

对于E.S.T办公时间，请拨打+1-917-300-0470（对于美国）/CAN免费电话+1-800-526-8630（对于GMT办公时间），请拨打+353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

U、 美国传真：646-607-1907传真（美国境外）：+353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

徽标：https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

来源研究和市场